AMRN logo

AMRN Amarin Corp - ADR

$13.20
$0.23
(1.71%)
Today
Closed $13.20
$0.00
(0.00%)
After Hours
43

Bearish Sentiment

How do you feel about AMRN?

Loading...
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.
Zacks
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Zacks
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Zacks
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
Zacks
Amarin (AMRN) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Zacks
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
BHC beats Q2 estimates as Salix, Solta Medical and Bausch + Lomb fuel growth, lifting 2026 revenue and EBITDA guidance after strong earnings.
Zacks
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.
Zacks